All posts by imreal

Business: Insurance

Top Reasons For Having Car Insurance Claims Denied

Leave a comment


News Image

“Missing payments, fronting or using a personal vehicle for business are solid grounds for having a claim rejected. But they are not the only reasons,” said Russell Rabichev, Marketing Director of Internet Marketing Company.


Los Angeles, CA (PRWEB)

Car insurance claims are denied for not respecting the terms of the contract or lying to the insurer. Having a claim denied means that the policyholder will pay everything from his own finances. Find out more about the top reasons for a claim denial and get free quotes from http://compare-autoinsurance.org

An insurance company may choose to deny a claim for the following reasons:


  •     Policy limits. Drivers should always be aware of coverage limits. The company will not reimburse any damage beyond the coverage limits. They will pay the maximum limits and the difference will have to be paid by the policyholder. Those limits are selected when a car insurance was purchased.

  •     The vehicle was driven by an undocumented driver. All drivers must be declared in the contract. Any other person that drives the car and is involved in an accident will not be covered. The most common scenario is when the policyholder lets a friend or relative use the car and he gets involved in an accident. Insurance companies will reject ulterior claims.

  •     Missing premium payments. If the policyholder no longer pays the premiums he is no longer covered and his claim will be rejected. Furthermore, not paying the premiums may determine the insurer to cancel coverage and cause an insurance lapse. Insurance companies consider drivers with recent lapses “high-risk”.

  •     Unapproved customization. The client can void the entire coverage if he installs different parts and devices without informing the insurer and getting its approval. Customizing the engine and fuel systems are likely to make the insurer drop the client if they are done without the company’s consent. Talk with the insurance company before adding customized parts. Many companies even offer customized-equipment coverage.

  •     Claims for coverage that was not purchased. Each policy covers only specific events. For example, collision coverage will not cover damage caused by fire or earthquakes. Carefully read the terms of the contract and ask representatives about all covered scenarios.

  •     The personal vehicle used for business Most vehicles are insured for private use, which includes using it to get to and from work on a daily basis. If the policyholder will be using the vehicle during the day to perform your work duties, this will have to be disclosed. Otherwise, if the car is involved in an accident while performing work duties, ulterior claims will be rejected.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

For more information, please visit http://compare-autoinsurance.org

Share article on social media or email:

Health

Project HOPE Team in China Readies for Arrival of Over 2 Million Masks and Other Protective Gear Bound for Doctors and Nurses in Wuhan

Leave a comment


Project HOPE

“Working together with MAP International, MedShare, and UPS, we are delivering one of the first large-scale international aid shipments to reach the doctors and nurses in Wuhan,” said Rabih Torbay, President and CEO of Project HOPE.


MILLWOOD, Va. (PRWEB)

As China’s coronavirus cases continue to climb, Project HOPE’s team in China is ramping up to receive the first of several shipments of personal protective equipment destined for doctors and nurses battling the novel coronavirus outbreak.

This first shipment contains more than 2 million respirator masks, 11,000 protective suits, and 280,000 pairs of nitrile gloves donated by MAP International and MedShare. Thanks to in-kind transport from UPS, the supplies are scheduled to arrive in Shanghai on Sunday, February 2. Project HOPE, which has worked in China since 1983, will support delivery of the supplies to Hubei Provincial Center for Disease Control and Prevention and onward to hospitals in Wuhan.

“Working together with MAP International, MedShare, and UPS, we are delivering one of the first large-scale international aid shipments to reach the doctors and nurses in Wuhan,” said Rabih Torbay, President and CEO of Project HOPE. “The skyrocketing demand for personal protective equipment has decimated the stockpiles at many health facilities in China, and this shipment will help shore up supplies in Wuhan so more patients can be safely screened and treated.”

Project HOPE has a long history in Wuhan, having collaborated with Wuhan University for nearly 20 years to establish the HOPE School of Nursing — one of its strongest and longest-running health workforce programs, which has trained thousands of nurses. Many of the nurses trained at the HOPE School of Nursing are now tirelessly working to screen and treat those with flu-like symptoms at hospitals in Wuhan.

Project HOPE is working to facilitate additional airlifts of supplies that will arrive in China in the days to come. Our team in China continues to work in close coordination with local officials to learn additional ways we can support health workers and health systems in areas affected by the new coronavirus outbreak.

For more information on our response to the coronavirus outbreak, visit [http://www.projecthope.org.

Share article on social media or email:

Industry: Healthcare

Litiscape Protects Physicians by Vetting Patients for Litigation Risk

Leave a comment


The founder and CEO of Litiscape, Michael Kamalu.

“My goal is for physicians to be able to perform their job to the best of their ability without fear of vulnerability and exploitation,” Kamalu said. “Litiscape will provide physicians with peace of mind again, while also enabling them to provide the best-informed care for their patients.”


PHOENIX, Ariz. (PRWEB)

Litiscape, a new software company created to protect physicians from frivolous malpractice litigation and financial exploitation, launched this month. By screening for over 1,200 different liability factors in real time, Litiscape provides physicians with information that allows them to both protect themselves and give better care to their patients.

The program’s creator, Michael Kamalu, thought of the concept after his father, a private practice family physician, was hit with his fourth malpractice suit. After months of stress and damage to his practice, he discovered the patient had a long history of filing baseless lawsuits in pursuit of monetary payouts. Utilizing his business and medical school background, Kamalu created Litiscape so that physicians wouldn’t have to be blind to high risk situations and even exploitation. He’s also partnered with malpractice insurance carriers to provide physicians who use their software with a significantly discounted insurance policy, saving them a considerable amount of money.

“Unfortunately, the malpractice system incentivizes frivolous litigation,” Kamalu said. “Less than 15% of claims ever show any evidence of medical error, yet 97% of patient plaintiffs receive monetary payouts. Some people justify it by saying malpractice insurance pays the claims so it doesn’t have any significant effect on physicians, but that couldn’t be further from the truth. Premiums go up, countless hours are wasted, carefully groomed reputation is damaged, and in some cases, careers have been ruined. With Litiscape, we are putting some control back in the hands of physicians so that they can have the peace of mind to focus on what they became a doctor for – to help and to heal.”

Litiscape has a proprietary algorithm that calculates a risk profile based on numerous factors including past litigation history, fraud and criminal records. The software also notifies physicians of potential healthcare-influencing factors such as DUIs, prescription fraud, or drug arrests, even detailing what type of drug was involved such as narcotics, barbiturates, or amphetamines. With this knowledge, a physician can be on the lookout for drug-related symptoms and also be aware of which prescriptions may not be appropriate to prescribe.

“My goal is for physicians to be able to perform their job to the best of their ability without fear of vulnerability and exploitation,” Kamalu said. “Litiscape will provide physicians with peace of mind again, while also enabling them to provide the best-informed care for their patients. We believe it will soon become a new standard in the healthcare industry.”

About Litiscape

Litiscape’s core product is a software that allows physicians to vet prospective patients for potential liabilities – analyzing and weighing over 1,200 distinct background factors in real-time, and categorizing them by litigation risk, financial risk, criminal risk, and healthcare-influencing factors. By pulling from every public record and court database across the country, physicians have access to invaluable insights into everyone they treat. Litiscape is redefining the standard in provider protection and informed care. To learn more, visit http://www.litiscape.com.

Share article on social media or email:

Business: Executives

Bricata Names John Becker Executive Chair of its Board of Directors

Leave a comment


“We’re extremely pleased to have John in this board leadership role,” said Bricata CEO John Trauth. “John’s exceptional cybersecurity experience and industry knowledge is a key factor in Bricata’s sustained customer and product growth.”


COLUMBIA, Md. (PRWEB)

Bricata, Inc., a leading provider of comprehensive network protection, today announced it has named John Becker as executive chair of its board of directors. Over the course of his career, Becker has an extensive track record of successfully leading companies in the development of breakthrough technologies and achieving accelerated growth.

“We’re extremely pleased to have John in this board leadership role,” said Bricata CEO John Trauth. “John’s exceptional cybersecurity experience and industry knowledge is a key factor in Bricata’s sustained customer and product growth.”

Becker has served as the chief executive officer at companies including Sourcefire, ScienceLogic, Approva Corporation, Arbor Networks, Cybertrust, TruSecure and AXENT Technologies. He has served as a Bricata board member since July 2017.

“Bricata’s solution delivers the critical network visibility and context needed to protect organizations in today’s evolving and increasing threat landscape,” said John Becker, executive chair of the Bricata Board of Directors. “In the last 12 months, the company has released a new version of its platform, added key new executives to its leadership team, strengthened partnerships, and earned industry analyst recognition for its innovation in network traffic analysis and intrusion detection and prevention systems. I look forward to continuing to work with the Bricata team as they further develop the state-of-the-art in network protection.”

About Bricata

Bricata is the leader in comprehensive network protection. The Bricata solution provides unparalleled network visibility, full-spectrum threat detection, threat hunting and post-detection response capabilities in an intuitive, tightly integrated and self-managing system. Its automated detection, productive GUIs, and expert system workflows make it easy-to-use for novices, while granular control of its engines, access to rich network metadata and PCAPs, and true threat hunting capabilities give experts the power and control they demand. Bricata has been proven to speed incident resolution by up to eight times by reliably detecting threats and providing the context necessary to get to the truth quickly and act. For more information visit http://www.bricata.com.

Share article on social media or email:

Industry: Healthcare

Immunitor publishes interim results from Phase III trial of oral immunotherapy for liver cancer

Leave a comment


What makes this investigation standing apart from immunotherapeutic approaches in oncology is that it attacks the problem from a new angle not attempted before


VANCOUVER, British Columbia (PRWEB)

Liver cancer, called hepatocellular carcinoma (HCC), occurs each year in more than 800,000 people around the world and about 700,000 die from the disease. HCC is the 5th most common cancer and the 2nd leading cause of cancer deaths. Mongolia firmly occupies the first place among all countries when it comes to incidence of HCC, while China has half of all patients suffering from liver cancer. The incidence of HCC is expected to rise in the United States and across the world, given the increasing prevalence of hepatitis C and B infections, alcohol consumption, NASH, diabetes, toxin exposure and obesity. By the time diagnosis of HCC is made, various surgical interventions or liver transplantation are often not feasible. Conventional systemic chemotherapy such as sorafenib, regorafenib, lenvatinib, and cabozantinib are seldom effective and quite toxic. The FDA has recently approved three antibody-based drugs for HCC indication: nivolumab, pembrolizumab, and ramucirumab. Additional immune interventions from the checkpoint inhibitor family, i.e., durvalumab, atezolizumab, and bevacizumab, as well as tremelimumab, which belongs to the anti-CTLA4 class, are being investigated. Experience has shown that none of the currently approved or experimental HCC drugs are free from adverse side effects and have limited effect in shrinking tumors. While we have witnessed a surge of systemic therapies in recent years, the need for safer and truly effective treatment remains.

The Immunitor study is published in January issue of Hepatoma Research(ClinicalTrials.gov Identifier: NCT02232490). Easy-to-use, once-per-day oral tableted therapeutic vaccine called hepcortespenlisimut-L (V5 or Hepko-V5) was developed by Vancouver-based Immunitor Inc in collaboration with medical team at the National Cancer Center in Mongolia and investigators in the USA, China and Thailand. This trial is continuation of successful 75-patient Phase II trial published in 2017 in the Journal of Hepatocellular Carcinoma. Anti-HCC property of V5 was discovered accidentally ten years ago during clinical use for original primary indications, which are chronic viral hepatitis and liver cirrhosis. V5 has been used by over 30,000 individuals since 2002 and has never been reported of causing any serious adverse reactions. The US FDA granted Hepko-V5 orphan drug designation status in 2014. V5 inherently incorporates all circulating antigens from pooled blood of HCC patients, including tumor unrelated immunogens such as viral hepatitis antigens, microbial antigens such as Mycobacterium TB, and alloantigens, which are not necessarily pathogenic. A version of V5 also known as Tubimod is approved by US FDA for immunotherapy of tuberculosis – most prevalent infectious disease in the world.

“What makes this investigation standing apart from current immunotherapeutic approaches in oncology is that it attacks the problem from a new angle that has not been attempted before. Our goal is to demonstrate that oral allogeneic vaccine delivery induces both the immune activation and at the same time the tolerance, which is the counterintuitive approach against paradigm dominating the field of immuno-oncology,” said Dr Aldar Bourinbaiar – the CEO of Immunitor. “We firmly believe that our approach makes sense since we see drastically higher response rate and unprecedented safety unlike anything published in in the past. Our investigation of hepcortespenlisimut-L is in its early stage and we are sure we will make more surprising discoveries down the road. Besides the profound influence on the immune response, which is expected from cancer vaccines, we see very clear clinical benefits in terms of improved liver function and decrease in tumor marker alphafetoprotein (AFP), which we have shown to be correlated with tumor regression. Indeed, when AFP levels in a patient are back to normal levels the tumor disappears.”

About Immunitor

Canada-based Immunitor is a private biopharmaceutical company with affiliations in USA, Russia, China, Hong Kong, Ukraine, Mongolia and South Africa. Immunitor has developed unique oral delivery platform and is among the top ten leading oral vaccine companies globally. Company has an extensive pipeline of 22 oral immunotherapy products at various stages of development, including many already commercialized. Immunitor’s therapeutic vaccines are made as ordinary appearing tablets or pills stable at room temperature for years. They are broadly split into three clinical categories: infectious diseases, metabolic/ inflammatory/autoimmune disorders and oncology indications (cancers affecting lungs, breast, liver, pancreas, gallbladder ducts, GI tract, kidneys, ovaries, cervix, brain, sarcoma, multiple myeloma, etc. For more information, please write at info@immunitor.com.

Share article on social media or email:

Business: Executives

Brandenberry Announces Occasional Tables with Built-In Security Feature

Leave a comment


Amish Custom Perry Occasional Table Collection

The gun vault is one of the security package options of the Perry Occasional Table Collection.

With hidden drawers, locked safes and other safety features, the Perry Occasional Table Collection gives homeowners the opportunity to store precious items in plain sight.


SHIPSHEWANA, Ind. (PRWEB)

What are the chances that a thief who breaks into a home would rip apart the living room tables in search for precious items like jewelry, rare coins or money? Such a likelihood is very low. And that’s the point of the security package available with the Perry Occasional Table Collection from Brandenberry Amish Furniture of Shipshewana, Indiana.

The security package is an optional feature of the Perry Occasional Table Collection. And it can be included in any of the tables. Amish cabinetmakers custom-build the drawers with 100-lb. ball bearing slides for hefty storage. Also, the drawers are built with dovetail joints, which are unrivaled in strength and durability.

Several secure storage options are available. They include a platform pullout. Plus an electronic safe and a trigger lock. This unique storage system frees one up to store valuables or a handgun safely – and in a place intruders would not ordinarily look for them.

“With hidden drawers, locked safes and other safety features, the Perry Occasional Table Collection gives homeowners the opportunity to store precious items in plain sight,” says Floyd Eash, furniture consultant at Brandenberry Amish Furniture.

The drawer fronts occupy the full width of space between the legs on the end of the table. So they blend seamlessly into the table design. And if no hardware is added, the drawers remain incognito.

Of course, the Perry Occasional Table Collection can be ordered without the security package. In this case, customers may wish to order the standard drawers with hardware. And there are numerous hardware options to choose from.

Security package aside, the Perry Occasional Table Collection makes a statement of elegance and sophistication. It features gently bowed legs, graceful arches and simple lines. So the collection is ideally suited for any upscale living room or family room. The collection includes a coffee table and sofa table, plus a tall and short end table and a tall and short nightstand. This gives furniture buyers real flexibility in choosing the tables that fit their needs and desires.

Skilled Amish cabinetmakers custom-build the Perry Occasional Table Collection. The Amish men use quality hardwoods such as oak, cherry and maple. The collection is incredibly sturdy, durable and a future family heirloom. The tables can be ordered online or by visiting Brandenberry Amish Furniture’s physical store in Shipshewana, Indiana. Homeowners can customize the Perry Living Room Collection. Custom preferences include the wood specie, finish and hardware.

About Brandenberry Amish Furniture:

Brandenberry Amish Furniture is located at 1045 N. State Road 5 in Shipshewana, at the intersection of State Road 5 and US 20, near the Indiana Toll Road. The store is open Monday through Saturday from 9 a.m. to 5 p.m. and by appointment.

Brandenberry Furniture opened its doors in 2008. The Brandenberry Furniture concept allows customers to design the furniture of their dreams…to explore the rich woods and stains that only nature can offer. Nothing matches the feel, the smell and the weight of hickory, oak, cherry, maple…real woods that come to life in an Amish handcrafted piece. They are meant to last a lifetime and beyond.

Whether a customer’s favorite style is Mission, Traditional, Modern or something in between, if Brandenberry Furniture doesn’t carry it, their craftsmen will build it to specification.

Brandenberry Furniture offers everything from bedroom and dining collections to home accessories, patio and exclusive furniture pieces. Browse Brandenberry Amish Furniture’s easy-to-use website with detailed photographs and information, and you’ll find furniture categorized by room (including family room, dining room, bedroom, office, children’s) as well as by wood species (including oak, hickory, cherry, elm, maple, pine and cedar) and style.

Share article on social media or email:

Health

2020 Top Dentists Issue of Healthy Living Magazine Now Available

Leave a comment


2020 Top Dentist’s Edition of Healthy Living Magazine

2020 Top Dentist’s Edition of Healthy Living Magazine


SCOTCH PLAINS, N.J. (PRWEB)

NJ Top Dentists has just released the latest Top Dentists issue of Healthy Living Magazine which features all 985 reviewed and approved New Jersey Top Dentists for 2020.

NJ Top Dentists is an exclusive healthcare resource that reviews healthcare providers in the state of New Jersey based on merit, not popularity. Each provider is put through a rigorous application and review process that includes but is not limited it, a minimum of 5 years in practice, a clean license, no significant malpractice issues, and generally stellar patient reviews. To view all reviewed and approved 2020 NJ Top Dentists, please turn to page 52 in the digital edition. To learn more about our methodology please visit our Review process.

All providers are reviewed at no cost to them and if approved listed in the magazine directory as an approved provider also at no cost to them. We also offer the magazine free to the public via direct in home distribution (across all 21 counties of New Jersey) and free subscriptions. You can click here to subscribe to Healthy Living Magazine for free and the next issue will be delivered to your doorstep. If you prefer to read the latest issue digitally, you can do so here.

The newly released issue also features fun-to-read articles on tools to keep your pet’s teeth squeaky clean, snow day recipes, eco-friendly dental options and more.

The goal of NJ Top Dentists’ magazine, Healthy Living is to provide New Jersey residents with a complete informational resource to assist them in choosing a local highly qualified healthcare provider at no cost. To take a look at all past and present Healthy Living issues, please click here.

Don’t forget to subscribe to receive a no cost printed copy of the next issue of Healthy Living featuring all NJ Top Doctors & Dentists which comes out in the Fall of 2020.

About Us

NJ Top Dentists is a division of NJ Top Docs. NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



Industry: Healthcare

Immunitor unveils breakthrough immunotherapy to treat tuberculosis in as short as one month

Leave a comment


This is first-ever TB vaccine available as a low-cost pill


VANCOUVER, British Columbia (PRWEB)

Immunitor Inc., commercial-stage biotech company, is pleased to announce the publication of positive results from the randomized, placebo-controlled Phase III clinical trial for Tubivac (V7), the first-in-class, orally-available therapeutic vaccine used as an immune adjunct for the chemotherapy of tuberculosis (TB). Tubivac consists of inactivated non-pathogenic strain of Mycobacterium vaccae, which is related to Mycobacterium tuberculosis – the pathogen that causes tuberculosis – most prevalent infectious disease affecting 10 million people every year. In addition, approximately 2 billion people, equivalent to roughly one quarter of the global population, are estimated to harbor a latent TB infection and therefore at risk of progressing to overt tuberculosis. The global spread of multi-drug-resistant (MDR) strains and co-infection with HIV also contributes to the challenges of treating TB – top infection in the world that killed 1.5 million people in 2018. The daily pill of Tubivac taken along with standard TB drugs has cleared TB bacteria within one month – the shortest treatment course available today. Currently, 6 months is required to treat drug-sensitive TB and at least 12 months for MDR-TB, which benefits 85% and 50% of patients respectively – the rates Tubivac can achieve after just one month.

The published trial confirmed safety and efficacy of two earlier Phase II studies of V7 at same 10 microgram per dosage strength. “This is first-ever TB vaccine available as a low-cost pill”, said Dr. Aldar Bourinbaiar, CEO of Immunitor. “Tubivac is a result of our earnest effort to address the unmet need for faster-acting regimens to treat all forms of tuberculosis including drug-resistant TB and TB with HIV. The anti-TB property of Mycobacterium vaccae strain used in this trial was first discovered in 1972 by Cynthia and John Stanford during Buruli ulcer outbreak in Uganda. The positive data from our trial, published in Elsevier’s Journal of Clinical Tuberculosis and Other Mycobacterial Diseases is a culmination of 10 years of altruistic endeavor aimed at developing oral immunotherapy with a novel mechanism of action that can alleviate suffering of people with TB. Our study has shown that Tubivac helps gain weight, reduce inflammation, and can counteract hepatotoxicity commonly caused by TB drugs. In addition, our clinical experience shows that Tubivac has a potential to treat asthma, emphysema, COPD, lung cancer and fibrosis – other serious medical conditions affecting lungs. Nothing principally new, since introduction of BCG vaccine in 1921 and deployment of TB antibiotics from 1940’s, has been developed to eradicate TB, which remains the number one killer disease today. Tubivac is faster, safer and cheaper of any TB interventions introduced so far and poised to be the paradigm shifter.”

About Immunitor

Canada-based Immunitor is a private biopharmaceutical company with affiliations in USA, Russia, China, Hong Kong, Ukraine, Mongolia and South Africa. Immunitor has developed unique oral delivery platform and is among top ten oral vaccine companies globally. Company has an extensive pipeline of twenty two oral immunotherapy products at various stages of development, including several already commercialized. Immunitor’s therapeutic vaccines are made as ordinary appearing pills stable at room temperature for years. They are broadly split into three clinical categories: infectious diseases; viral, bacterial, fungal and protozoan, metabolic/autoimmune/inflammatory disorders; atherosclerosis, diabetes, obesity, hypertension, psoriasis, endometriosis, etc. and oncology indications, e.g., cancers affecting lungs, breast, liver, pancreas, gallbladder ducts, GI tract, kidneys, ovaries, cervix, brain, multiple myeloma, etc. The development of three products was supported by Global Grand Challenges initiative from Bill and Melinda Gates Foundation, financed by the government of Canada. Immunitor currently offers for sale Ukrainian-made Immunoxel (Dzherelo) – immunomodulating phytoconcentrate and in-house developed Tubimod (V5), both of which were shown in Phase III trials to reduce the duration of TB treatment down to one month. Tubivac (V7) is yet another proprietary, orally formulated anti-TB orphan drug with shorter treatment duration. The injectable form of M. vaccae has been through over hundred clinical trials in more than 20 countries since 1980’s – however this inconvenient-to-use formula is twice-less effective and sold in China under VACCAE trademark by Anhui Zhifei Longcom – a company that has been inspired by John Stanford’s pioneering work. For more information, please write at info@immunitor.com.

Share article on social media or email:

Business: Executives

Marketing Maven Founder To Participate in PRSA-LA’s State of the State of PR

Leave a comment


Lindsey Carnett

“I am honored to have been selected as part of this important panel,” said Lindsey Carnett, Marketing Maven CEO and President. “It is essential to educate the public on the ways social media has transformed personal and business communications.”


LOS ANGELES (PRWEB)

Lindsey Carnett, CEO and President of bicoastal, award-winning public relations firm Marketing Maven, will be among the social media rock stars and industry disrupters on the panel at PRSA-LA’s State of the State of PR event in downtown Los Angeles.

The panel, Tweet, Like and Share—How Social Media Has Disrupted Public Relations—will be the feature presentation at the event, which will take place Thursday, February 6, 2020 from 6pm to 9pm PST. The location is WeWork, 5792 Jefferson in Los Angeles.

The panelists will discuss how social media has literally changed the world, thus providing new ways people communicate, how one receives news and promotes projects, and a look at what’s to come.

“I am honored to have been selected as part of this important panel,” said Carnett. “It is essential to educate the public on the ways social media has transformed personal and business communications.”

Named a Top Woman in Public Relations by PR News, a FOLIO: Magazine 2015 Top Woman in Media and featured in the Forbes Most Powerful Women Business Leader issue, Carnett has taken her business expertise globally to enlighten marketing peers, clients and students about best practices in using PR, social media and influencer marketing to drive revenue, improve organic SEO and grow a positive online reputation.

She has appeared on TheStreet.com, National Public Radio (NPR), The Doctors, The Jeff Probst Show, Telemundo, and local ABC, NBC and CBS morning news programs, as well as USA Today, PR Week, Forbes Woman, Medium and Thrive Global among others. Carnett also contributes to Forbes.com and Natural Products INSIDER. She teaches the social media content course at Academy of Art University.

Marketing Maven was named to the 2018 and 2017 Inc. 5000 List of Fastest Growing Private Companies, as well as the 2016 Entrepreneur 360 list of “Best Entrepreneurial Companies in America.”

A graduate of the Goldman Sachs 10,000 Small Businesses program and current VISTAGE and Women Presidents’ Organization member, Carnett also serves as Professional Adviser to the Public Relations Student Society of America (PRSSA). Previous Board roles include the National Association of Women Business Owners, Los Angeles (NAWBO-LA), the Electronic Retailing Association (ERA) and Women in Sports and Events (WISE) Los Angeles. Her business certifications include WBE, WOSB, 8(a), DBE, CPUC, Metro and WBENC.

Tickets to PRSA-LA’s State of the State of PR can be purchased here bit.ly/2Gksikv

About Marketing Maven

With offices in Los Angeles and New York, Marketing Maven is a full-service marketing and communications agency. With origins in direct response public relations, Marketing Maven has developed into a premier voice in brand strategy, social media, innovative media relations, event marketing, tradeshow support, Hispanic marketing and search engine optimization. Marketing Maven leads the industry in utilizing advanced metrics to measure their clients’ marketing reach and providing competitive analysis unparalleled in the industry. For additional information about Marketing Maven, visit http://www.MarketingMaven.com.

About PRSA-LA

The Los Angeles Chapter of the Public Relations Society of America (PRSA-LA) is comprised of nearly 600 agency, in-house and independent public relations professionals representing LA-area corporations, academic institutions, government agencies and nonprofit organizations.

PRSA-LA was established in 1948 as one of PRSA’s first five founding chapters. Members benefit from chapter events, educational and networking opportunities, industry advocacy and a wide range of professional development resources.

Share article on social media or email:

Health

Thornberry’s NDoc® EMR ranked #1 again!

Leave a comment


Thornberry and 7 KLAS logos - 2020

Thornberry has been ranked #1 since 2013

Seven years in a row! We are both humbled and thrilled to be top-ranked by KLAS again this year.


LANCASTER, Pa. (PRWEB)

Thornberry Ltd has been rated #1 by customers once again, making it seven in a row for the company’s NDoc® home health and hospice EMR.

Thornberry first set the record in 2017 with a fourth consecutive “Best in KLAS” award for the homecare segment, and it continues to leave the competition behind. Thornberry’s home health and hospice EMR received a top-ranked score of 90.4 in the 2020 Best in KLAS: Software & Services report, surpassing the average for the segment by more than nine points.

This year, NDoc won the KLAS Category Leader award for the new Home Health & Hospice (Small) market segment. While not an official competitor in the new “large” market because NDoc data is limited for that segment, Thornberry scored the highest in either category, keeping them ahead of the competition for the seventh year in a row.

“Seven years in a row! We are both humbled and thrilled to be top-ranked by KLAS again this year,” said Thornberry President and CEO Tom Peth, “and we’d like to thank our providers once again. We couldn’t be #1 year after year without their loyal partnership and support, which in turn would not be possible without the dedication and hard work of our Thornberry team.” Peth continued, “We continue to take pride in providing innovative technology and top-level service; this award lets us know we’re doing a lot of things right and how to continue our commitment to the growth and success of our customers.”

KLAS winners are determined through extensive surveys and interviews with healthcare providers on the efficiency and quality of health IT products. KLAS Research methodology evaluates and ranks vendors in six key categories: Culture, Product, Relationship, Operations, Loyalty, and Value. Once again, Thornberry received A ratings in more categories than any other vendor. “I can’t say enough about the service and response that we get from Thornberry,” commented one Director in October 2019. “Thornberry’s responsiveness really sets them apart… NDoc seems to be light-years ahead of other products. Thornberry’s service is second to none.” Clinical users agree. In December 2019 a Nurse user commented: “The support is unbeatable; it is above and beyond anything I have ever seen.”

The Best in KLAS and Category Leader designations are a recognition of outstanding efforts to help healthcare organizations in their quest to deliver quality patient care. Category Leader awards are offered in new segments with a focused impact across many health systems. “Providers and payers demand better performance, usability, and interoperability from their vendor partners every year,” says KLAS President Adam Gale. A KLAS award sets the standard of excellence in a market segment, Gale adds: “It serves as a signal to providers that they should expect only the best from the winning vendors.”

Thornberry will be recognized for its record-breaking win at the annual Best in KLAS awards reception at HIMSS on March 9 in Orlando, FL.

About Thornberry

In the 27 years since its founding, Thornberry has become an innovative and respected leader in both certification and interoperability, providing a complete suite of innovative tools for homecare and hospice through its NDoc® software solution. Top-ranked by KLAS for the seventh year in a row, NDoc is a CCHIT Certified Long Term and Post-Acute Care (LTPAC) EMR additionally certified for Home Health. Learn more about the powerful, flexible, and comprehensive NDoc solution at ndocsoftware.com.

About KLAS

KLAS is a data-driven company on a mission to improve the world’s healthcare by enabling provider and payer voices to be heard and counted. Working with thousands of healthcare professionals, KLAS collects insights on software, services and medical equipment to deliver reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly reflects the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit KLASresearch.com.

Share article on social media or email: